# Effect of Intracoronary N-Acetylcysteine in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

> **NCT06850831** · PHASE2 · COMPLETED · sponsor: **dr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FA** · enrollment: 70 (actual)

## Conditions studied

- STEMI - ST Elevation Myocardial Infarction (MI)
- Primary PCI - STEMI

## Interventions

- **DRUG:** Antipac

## Key facts

- **NCT ID:** NCT06850831
- **Lead sponsor:** dr. Ahmad Yasa, Sp.JP, Subsp.K.I.(K), M.Kes, FIHA, FasCC, FA
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-04-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2025-12-07
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850831, "Effect of Intracoronary N-Acetylcysteine in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06850831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*